Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 4/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 2/20 | 0.30 |
| ▸ | CLK3 | P49761 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776167 | 0.83 | FGFR4 (0.43) | DYRK1AGSK3BCYP3A4PORCNABL1 | |
| SCHEMBL16776216 | 0.81 | ABL1 (0.34) | CYP3A4CYP11B2ABL1AKT1 | |
| SCHEMBL16776038 | 0.81 | CNR1 (0.36) | ABL1 | |
| SCHEMBL16776201 | 0.81 | FGFR4 (0.42) | DYRK1AGSK3BCHRNA7KCNH2CYP3A4 | |
| SCHEMBL16776141 | 0.79 | FGFR4 (0.46) | DYRK1AGSK3BKCNH2CYP3A4PORCN | |
| SCHEMBL16776185 | 0.79 | HTR2C (0.40) | DYRK1ACYP3A4CYP11B2ABL1 | |
| SCHEMBL16776140 | 0.79 | DYRK1A (0.37) | DYRK1AGSK3BCHRNA7KCNH2CYP3A4 | |
| SCHEMBL16776138 | 0.78 | PRMT5 (0.33) | — | |
| SCHEMBL16776119 | 0.78 | FGFR4 (0.43) | DYRK1AGSK3BCYP3A4PORCNCYP11B2 | |
| SCHEMBL16776011 | 0.76 | CA9 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | DYRK1A 2623/4885GSK3B 1728/4885CHRNA7 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.